Kodiak Sciences Inc

The asset is deeply oversold within an uptrend and mean reversion eligible, supporting a bullish medium-term bias. Short-term price behavior shows extension below short-term EMAs and RSI at oversold levels; execution is deferred pending evidence of support acceptance at the 200-day SMA or key horizontal pivot. Overall, defer entry and stalk around pullback support areas within a bullish medium-term backdrop.

• ↑Upcoming Phase 3 (DAYBREAK, PEAK) readouts could validate ABC platform and boost demand
• ↑89% institutional ownership underpins price stability amid volatility
• ↓Q2 net loss widened to $1.05/sh and H1 loss reached $123.8M